Omicron Forces US FDA To Again Pause ‘Certain Inspectional Activities’
Executive Summary
COVID-19 pandemic’s latest variant has pushed FDA to pump brakes again on performing on-site surveillance inspections through at least 19 January. Meanwhile, associate commissioner says Remote Regulatory Assessments “are here to stay.”